Table 1 Clinical and histopathological characteristics of 548 patients with colon cancer and the 346 patients with pN0 colon cancer within them grouped into 3 risk-groups according to their final error probability
From: Modelling the probability of erroneous negative lymph node staging in patients with colon cancer
Characteristic | Low-risk group (FEP < 2%) | Intermediate-risk group (FEP 2%–15%) | High-risk group (FEP > 15%) | Entire cohort | P value |
|---|---|---|---|---|---|
Number of cases | 35 | 244 | 67 | 548 | |
Age [years, median (range)] | 66 (41–84) | 74 (30–95) | 76 (41–95) | 72 (30–95) | 0.002 |
Gender [cases (%)] | 0.322 | ||||
Male | 12 (34.3%) | 102 (41.8%) | 33 (49.3%) | 296 (54.0%) | |
Female | 23 (65.7%) | 142 (58.2%) | 34 (50.7%) | 252 (46.0%) | |
Tumour location [cases (%)] | 0.001 | ||||
Right colon | 18 (51.4%) | 108 (44.3%) | 14 (20.9%) | 224 (40.9%) | |
Left colon | 16 (45.7%) | 118 (48.4%) | 50 (74.6%) | 290 (52.9%) | |
Unknown | 1 (2.9%) | 18 (7.4%) | 3 (4.5%) | 34 (6.2%) | |
Tumour size (mm, mean ± SD) | 55 ± 30 | 48 ± 21 | 36 ± 19 | 46 ± 21 | < 0.001 |
Histological classification [cases (%)] | 0.344 | ||||
Adenocarcinoma | 29 (82.9%) | 206 (84.4%) | 62 (92.5%) | 465 (84.9%) | |
Mucinous variant | 6 (17.1%) | 33 (13.5%) | 5 (7.5%) | 74 (13.5%) | |
Signet-ring cell | 0 | 5 (2.0%) | 0 | 9 (1.6%) | |
Tumour differentiation grade [cases (%)] | 0.013 | ||||
Well | 11 (31.4%) | 70 (28.7%) | 33 (49.3%) | 151 (27.6%) | |
Moderate | 22 (62.9%) | 160 (65.6%) | 26 (38.8%) | 343 (62.6%) | |
Poor | 1 (2.9%) | 8 (3.3%) | 5 (7.5%) | 35 (6.4%) | |
Unknown | 1 (2.9%) | 6 (2.5%) | 3 (4.5%) | 19 (3.5%) | |
Lymphadenectomy | < 0.001 | ||||
Number of analysed LNs [median (range)] | 23 (19–45) | 11 (6–18) | 4 (1–5) | 10 (1–45) | |
< 12 analysed LNs [cases (%)] | 0 | 142 (58.2%) | 67 (100%) | 308 (56.2%) | |
≥ 12analysed LNs [cases (%)] | 35 (100%) | 102 (41.8%) | 0 | 240 (43.8%) | |
pT [6th edition, cases (%)] | 0.044 | ||||
pT1 | 1 (2.9%) | 18 (7.4%) | 12 (17.9%) | 31 (5.7%) | |
pT2 | 4 (11.4%) | 47 (19.3%) | 11 (16.4%) | 85 (15.5%) | |
pT3 | 28 (80%) | 158 (64.8%) | 34 (50.7%) | 367 (67.0%) | |
pT4 | 2 (5.7%) | 20 (8.2%) | 9 (13.4%) | 63 (11.5%) | |
pTx | 0 | 1 (0.4%) | 1 (1.5%) | 2 (0.4%) | |
pN [7th edition, cases (%)] | < 0.001 | ||||
pN0 | 35 (100%) | 244 (100%) | 67 (100%) | 346 (63.1%) | |
pN+ | 0 | 0 | 0 | 202 (36.9%) | |
pN1a | 0 | 0 | 0 | 73 (13.3%) | |
pN1b | 0 | 0 | 0 | 70 (12.8%) | |
pN2a | 0 | 0 | 0 | 33 (6.0%) | |
pN2b | 0 | 0 | 0 | 26 (4.7%) | |
Condensed TNM [7th edition, cases (%)] | 0.094 | ||||
I | 5 (14.3%) | 65 (26.6%) | 23 (34.3%) | 93 (17.0%) | |
II | 30 (85.7%) | 179 (73.4%) | 44 (65.7%) | 253 (46.2%) | |
III | 0 | 0 | 0 | 202 (36.9%) | |
Chemotherapy [cases (%)] | 0.300 | ||||
No | 26 (74.3%) | 197 (80.7%) | 58 (86.6%) | 371 (67.7%) | |
Yes | 9 (25.7%) | 47 (19.3%) | 9 (13.4%) | 177 (32.3%) | |
Overall mortality [cases (%)] | 0.019 | ||||
No | 29 (82.9%) | 162 (66.4%) | 37 (55.2%) | 334 (60.9%) | |
Yes | 6 (17.1%) | 82 (33.6%) | 30 (44.8%) | 214 (39.1%) | |
Overall recurrence [cases (%)] | 0.185 | ||||
No | 33 (94.3%) | 204 (83.6%) | 54 (80.6%) | 439 (80.1%) | |
Yes | 2 (5.7%) | 40 (16.4%) | 13 (19.4%) | 109 (19.9%) | |
Locoregional recurrence [cases (%)] | 0.215 | ||||
No | 35 (100%) | 224 (91.8%) | 62 (92.5%) | 509 (92.9%) | |
Yes | 0 | 20 (8.2%) | 5 (7.5%) | 39 (7.1%) | |
Metastasis [cases (%)] | 0.397 | ||||
No | 33 (94.3%) | 214 (87.7%) | 57 (85.1%) | 456 (83.2%) | |
Yes | 2 (5.7%) | 30 (12.3%) | 10 (14.9%) | 92 (16.8%) | |
Follow-up [months, median (range)] | 58 (3–95) | 51 (1–95) | 55 (1–91) | 51 (1–99) | 0.167 |